Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)
Updated: December 13, 2025 Milestone Pharmaceuticals Inc. (Nasdaq: MIST) just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™ (etripamil)—a self-administered nasal spray for adults to convert acute